GlobalData on MSN15d
EC approves AstraZeneca’s Fasenra for EGPA treatment
The European Commission (EC) has approved AstraZeneca's Fasenra (benralizumab) as an add-on therapy for adults with relapsing ...
MedPage Today3mon
Quick Quiz: Eosinophilic Granulomatosis with Polyangiitis
Can you do it? Can you ace these quiz questions about EGPA? They’re all derived from the current literature. At the end of the quiz, compare your score with those of your physician colleagues.
PharmiWeb16d
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...
Pharmabiz15d
European Union approves AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...
Hosted on MSN10mon
Vasculitis Medications: List of Options for Mild to Severe Symptoms
and Nucala might be part of the initial treatment for nonsevere EGPA-type vasculitis (eosinophilic granulomatosis with polyangiitis vasculitis). Rituxan is also an important example. It might be used, ...
PMLiVE9d
AstraZeneca’s Fasenra approved by EC to treat rare inflammatory disease EGPA
AstraZeneca’s Fasenra (benralizumab) has been approved by the European Commission (EC) to treat eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune-mediated inflammatory disease that ...
biopharma-reporter15d
AstraZeneca’s rare disease therapy Fasenra receives EU approval
The new treatment will be a competitor of GSK’s Nucala (mepolizumab), which was approved in 2018 as the first targeted ...
Yahoo Finance1mon
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)
Depemokimab is also being evaluated in late-stage studies for eosinophilic granulomatosis with polyangiitis and hyper-eosinophilic syndrome. Sales in GSK’s respiratory portfolio are currently ...
Medscape15d
Fasenra Approved in Europe for Rare Blood Vessel Disorder
It can now also be used as an add-on treatment in adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). Its original indication is as an add-on maintenance ...
Health.com1y
What Causes Swollen Glands (Lymph Nodes) in the Neck?
Amyloidosis. StatPearls Publishing; 2023. American Lung Association. Learn About Eosinophilic Granulomatosis with Polyangiitis (EGPA). National Institute of Arthritis and Musculoskeletal and Skin ...
Daily13d
AstraZeneca Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...